µÏÍþ¹ú¼Ê



    µÏÍþÖÆµÏÍþ¹ú¼Ê µÏÍþÖÆµÏÍþ¹ú¼Ê

    ¼ò ¤™
    • ¼ò
    • ·±
    • EN
    ¤œ
    Ïà¹ØÁ´½Ó
    • ½­ËÕºÀÉ­µÏÍþ¹ú¼ÊÒµ¼¯ÍÅÓÐÏÞ¹«Ë¾¥Y
    ÐÂÎÅ·¢²¼
    Press Release
    Ê×Ò³  >  ÐÂÎÅÖÐÐÄ  >  ÐÂÎÅ·¢²¼
    ELCC 2025 | µÏÍþÖÆµÏÍþ¹ú¼Ê°¢ÃÀÀÖ?6Ïî´´ÐÂÑо¿ÈëÑ¡£¬³ÖÐøÌ½Ë÷·ÇСϸ°û·Î°©ÁìÓòÖÎÁÆ·½°¸
    ·¢²¼ÈÕÆÚ£º2025/03/28
    ×ÖºÅ

    2025Äê3ÔÂ28ÈÕ£¬µÏÍþÖÆµÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾£¨ÒÔϼò³Æ¡°µÏÍþÖÆµÏÍþ¹ú¼Ê¡±£¬03692.HK£©Ðû²¼£¬°¢ÃÀÀÖ?£¨¼×»ÇËá°¢ÃÀÌæÄáÆ¬£©6Ïî´´ÐÂÑо¿ÈëÑ¡ÓÚµ±µØÊ±¼ä3ÔÂ26-29ÈÕÔÚ·¨¹ú°ÍÀèÕÙ¿ªµÄÅ·Ö޷ΰ©´ó»á£¨ELCC£©£¬ÄÚÈݺ­¸Ç°¢ÃÀÀÖ?ÔÚ·ÇСϸ°û·Î°©£¨NSCLC£©ÁìÓò¸¨ÖúÖÎÁÆ¡¢º±¼ûÍ»±äºÍÄ͵ÏÍþ¹ú¼ÊºóÖÎÁƵȷ½ÃæµÄÑ­Ö¤Ö¤¾Ý¡£ELCC´ó»áÊǷΰ©ÁìÓòµÄÖØÒª¹ú¼ÊѧÊõ»áÒéÖ®Ò»£¬Ö¼ÔÚΪÓë»áÕßÌṩÓëÐØ²¿Ö×ÁöÏà¹ØµÄ¸ßˮƽ½ÌÓý¿Î³ÌºÍ×îÐÂÑо¿½øÕ¹¡£


    ´´ÐÂÑо¿ 1




    ±êÌ⣺Adjuvant Aumolertinib for Resected EGFR-Mutated Stage IA2-¢óA Non-Small-Cell Lung Cancer: Updated Results From A Multiple-center Real-world Experience

    °¢ÃÀÌæÄḨÖúÖÎÁÆEGFRÃô¸ÐÍ»±ä¢ñA2 -¢óAÆÚ·ÇСϸ°û·Î°©£ºÀ´×Ô¶àÖÐÐÄÕæÊµÊÀ½ç¾­ÑéµÄ×îнá¹û

    ×÷ÕߣºÕÅÇìâù/ºú¼á Õã½­´óѧҽѧԺ¸½ÊôµÚÒ»Ò½Ôº

    ÏòÉÏ»¬¶¯ÔÄÀÀ

    ±¾Ñо¿Ö¼ÔÚÆÀ¼Û°¢ÃÀÌæÄḨÖúÖÎÁÆEGFRÃô¸ÐÍ»±ä¢ñA2 -¢óAÆÚ·ÇСϸ°û·Î°©£¨NSCLC£©»¼Õߵij¤ÆÚÁÆÐ§¼°°²È«ÐÔ¡£¹²ÄÉÈë288Àý»¼Õß¡£½ØÖ¹2024Äê12Ô£¬ÖÐÎ»Ëæ·Ãʱ¼äΪ28.3¸öÔ¡£×ܼÆ22Àý»¼Õß¼²²¡¸´·¢¡£×ÜÈËȺ4ÄêDFSÂÊΪ74.1%£¬¢ñÆÚ»¼Õß4ÄêDFSÂÊΪ82.7%¡£¢ñÆÚ»¼ÕßÖУ¬44%´æÔÚ¸ßΣ²¡ÀíÒòËØ£¬22.6%ÖÁÉÙ´æÔÚÒ»ÖÖ¸ßΣ²¡ÀíÒòËØ¡£×î³£¼ûµÄ¸ßΣÒòËØ°üÀ¨Ôà²ãÐØÄ¤ÇÖ·¸£¨21.7%£©¡¢Î¢ÈéÍ·³É·Ö£¨12.7%£©ºÍʵÐԳɷ֣¨7%£©¡£²»°é¸ßΣ²¡ÀíÒòËØ»¼ÕßDFSÏÔÖøÓÅÓÚ°é¸ßΣ²¡ÀíÒòËØµÄ»¼Õß (p=0.0001)£¬ÌáʾÑÓ³¤¸¨ÖúÖÎÁÆÊ±³¤¿ÉÄܶ԰é¸ßΣ²¡ÀíÒòËØ»¼Õ߸üÓÐÒæ¡£ÔÚ°¢ÃÀÌæÄáÖÎÁÆÆÚ¼ä䱨¸æ¡Ý3¼¶µÄ²»Á¼Ê¼þ¡£103Àý£¨35.9%£©»¼Õß³öÏÖ²»Á¼·´Ó¦£¬×î³£¼ûµÄΪƤÕ17.4%£©¡¢¸Î¹¦ÄÜÒì³££¨6.2%£©¡¢¿ÚÇ»À£Ññ£¨5.9%£©¡¢¸¹Ðº£¨5.2%£©¡£

    ´´ÐÂÑо¿ 2




    ±êÌ⣺MRD Evaluation of Aumolertinib in EGFR Mutation-positive Stage IB and Stage IA2-3 NSCLC After Complete Surgical Resection: A Multicenter, Single-arm, Open-lable Study

    MRDÆÀ¹À°¢ÃÀÌæÄáÓÃÓÚEGFRÍ»±äÑôÐÔµÄIBÆÚºÍIA2-3ÆÚ½þÈóÐÔNSCLCÊõºó¸¨ÖúÖÎÁƵĶàÖÐÐÄ¡¢¿ª·Å¡¢µ¥±ÛÁÙ´²Ñо¿

    ×÷Õߣº³Ì³¬ ÖÐɽ´óѧ¸½ÊôµÚÒ»Ò½Ôº

    ÏòÉÏ»¬¶¯ÔÄÀÀ

    ¶àÏî»Ø¹ËÐÔ·ÖÎö֤ʵÁ˰¢ÃÀÌæÄḨÖúÖÎÁÆÍêÈ«ÇгýµÄI-¢óAÆÚEGFRÍ»±äNSCLC»¼ÕßµÄÓÐЧÐԺͰ²È«ÐÔ¡£È»¶ø£¬Ê¹Óð¢ÃÀÌæÄá×÷ΪÍêÈ«ÇгýµÄIÆÚNSCLC¸¨ÖúÖÎÁƵÄǰհÐÔÊý¾ÝÈÔȱ·¦¡£±¾Ñо¿Ê×´ÎÔÚ¶àÖÐÐÄ¡¢µ¥±ÛÑо¿Öб¨µÀÁ˰¢ÃÀÌæÄḨÖúÖÎÁÆÍêÈ«ÇгýµÄEGFRÍ»±äIÆÚNSCLC»¼ÕßµÄÓÐЧÐԺͰ²È«ÐÔ¡£¹²Èë×é67Àý»¼Õߣ¬ÆäÖÐ46ÀýÁÆÐ§¿ÉÆÀ¹À¡£ÖÐλÄêÁä60Ë꣨·¶Î§: 44-70Ë꣩£¬78.3%ΪŮÐÔ¡£ÆäÖÐIAÆÚÕ¼±È67.4%£¨IA2 34.8%£»IA3 32.6%£©£¬IBÆÚÕ¼±È32.6%¡£EGFR 19del ºÍ21 L858R·Ö±ðÕ¼±È56.5% ºÍ39.1%¡£8Àý»¼Õß°é¸ßΣ²¡ÀíÒòËØ¡£ÖÁÊý¾Ý½ØÖ¹ÈÕ£¨2024Äê12ÔÂ20ÈÕ£©£¬ÖÐÎ»Ëæ·Ãʱ¼äΪ10.3¸öÔ¡£ËùÓл¼ÕßÈÔÔÚÖÎÁÆÖУ¬Î´¹Û²ìµ½¼²²¡¸´·¢£¬2ÄêDFSÂÊΪ100 %£¬3ÄêDFSÂÊ£¨Ö÷ÒªÑо¿Öյ㣩ÈÔÔÚ¹Û²ìÖС£29Àý£¨63%£©»¼Õß·¢ÉúAEs£¬´ó¶àΪ1-2¼¶¡£2Àý£¨4.3%£©»¼Õß·¢Éú3¼¶ÒÔÉÏTRAEs¡£Î´·¢ÏÖÐµİ²È«ÐźÅ¡£41Àý»¼ÕßÊõºóÖÁÉÙ½øÐÐ1´ÎMRD¼ì²â£¬ÆäÖÐ2Àý³õʼ¼ì²âΪÑôÐÔ£¬¾­°¢ÃÀÌæÄáÖÎÁƺóתΪÒõÐÔ¡£

    ´´ÐÂÑо¿ 3




    ±êÌ⣺Efficacy and Safety of Aumolertinib as Adjuvant Therapy in Resectable Stage I A NSCLC with High Risk Factors and EGFR-sensitizing Mutations (APPOINT)

    °¢ÃÀÌæÄḨÖúÖÎÁÆ¿ÉÇгýµÄIAÆÚº¬ÊµÌåºÍ/»ò΢ÈéÍ·³É·ÖEGFRÃô¸ÐÍ»±äµÄ·ÇСϸ°û·Î°©µÄÁÆÐ§ºÍ°²È«ÐÔÁÙ´²Ñо¿£¨APPOINT£©

    ×÷Õߣºº«±¦»Ý ÉϺ£ÐØ¿ÆÒ½Ôº

    ÏòÉÏ»¬¶¯ÔÄÀÀ

    APPOINTÑо¿£¨NCT04922138£©ÊÇÊ׸öË«±Û¡¢¶àÖÐÐÄÁÙ´²Ñо¿£¬Ö¼ÔÚ̽Ë÷Èý´úEGFR-TKI°¢ÃÀÌæÄḨÖúÖÎÁÆIAÆÚEGFRÍ»±ä°é¸ßΣ²¡ÀíÒòËØNSCLC»¼ÕßµÄÁÆÐ§Ó밲ȫÐÔ¡£±¾Ñо¿¹²Èë×é95Àý¾ßÓÐÖÁÉÙÒ»ÖÖ¸ßΣÒòËØ£¨ÊµÌåÐÍ¡¢Î¢ÈéÍ·×´ºÍ/»ò¸´ÔÓÏÙÌå³É·Ö£©µÄIAÆÚEGFRÍ»±äNSCLC»¼Õß¡£¸ùÖÎÐԷΰ©ÊÖÊõºó£¬A×é¿Ú·þ°¢ÃÀÌæÄá110mgÿÈÕÒ»´Î¸¨ÖúÖÎÁÆ£¬B×é¹Û²ìËæ·Ã£¬ÆäÖÐA×é46Àý£¬B×é49Àý¡£ÖÐλÄêÁä·Ö±ðΪ57ËêºÍ66Ë꣬ŮÐÔÕ¼±È·Ö±ðΪ62.2%ºÍ65.3%¡£ÖÐÎ»Ëæ·Ãʱ¼ä16.5¸öÔ£¬A×黼Õß¾ùδ³öÏÖÖ×Áö¸´·¢£¬¶øB×éÓÐ2Àý¸´·¢¡£1Äêר²¡DFSÂÊΪ100% vs 87%£¬1ÄêÖ×Áö¸´·¢·çÏÕΪ0% vs 12.8%¡£A×é34Àý»¼Õß³öÏÖ²»Á¼Ê¼þ£¨AE£©£¬Î´·¢Éú¡Ý3¼¶AE¡£³£¼ûÖÎÁÆÏà¹Ø²»Á¼Ê¼þ°üÀ¨¼¡ËἤøÉý¸ß£¨34.8%£©¡¢ÈéËáÍÑÇâøÉý¸ß£¨15.2%£©¡¢¸Î¹¦ÄÜËðÉË£¨10.9%£©ºÍ¿ÚÇ»À£Ññ£¨10.9%£©¡£

    ´´ÐÂÑо¿ 4




    ±êÌ⣺Safety and Efficacy of Aumolertinib Treatment in Patients with Advanced NSCLC Harboring 20ins and Uncommon EGFR Mutations (AIM) 

    °¢ÃÀÌæÄáÖÎÁÆÍíÆÚEGFR 20²åÈëºÍº±¼ûÍ»±äNSCLC»¼ÕßµÄÁÆÐ§ºÍ°²È«ÐÔ£¨AIM£©

    ×÷ÕߣºÕÅÁ¦/·½ÎÄ·å  ÖÐɽÖ×ÁöÒ½Ôº

    ÏòÉÏ»¬¶¯ÔÄÀÀ

    ±¾Ñо¿ÄÉÈëЯ´øEGFRº±¼ûÍ»±äµÄ¾Ö²¿ÍíÆÚ»ò×ªÒÆÐÔNSCLC»¼Õߣ¬·ÖΪÁ½×飺¶ÓÁÐ1Ϊ20insÍ»±ä£¬¶ÓÁÐ2ΪÆäËûº±¼ûÍ»±ä£¨ÈçG719X¡¢L861Q¡¢S768IµÈ£©¡£ÔÊÐí¼ÈÍù½ÓÊܹý¡Ü¶þÏß»¯ÁƵϼÕßÈë×é¡£»¼Õß½ÓÊܰ¢ÃÀÌæÄáµ¥µÏÍþ¹ú¼ÊÖÎÁÆ£¨165mg¿Ú·þÿÈÕÒ»´Î£©¡£¹²ÄÉÈë41Àý»¼Õߣ¬ÆäÖÐ33ÀýÄÉÈëÁÆÐ§·ÖÎö¼¯¡£¶ÓÁÐ1ºÍ¶ÓÁÐ2·Ö±ðÓÐ16ÀýºÍ17Àý»¼Õß¡£Á½×éÖÐλÄêÁä·Ö±ðΪ55Ë꣨38-75Ë꣩ºÍ58Ë꣨42-73Ë꣩£¬Å®ÐÔÕ¼±È·Ö±ðΪ68.8%ºÍ52.9%¡£¼ÈÍù½ÓÊÜ»¯ÁƵϼÕß·Ö±ðΪ4ÀýºÍ3Àý¡£¶ÓÁÐ1£ºORRΪ12.5%£¬DCRΪ100%£¬ÖÐλPFSΪ6.5¸öÔ£¬ÖÐλOSΪ20.6¸öÔ¡£¶ÓÁÐ2£ºORRΪ47.1%£¬DCRΪ100%£¬ÖÐλPFSΪ11.8¸öÔ£¬ÖÐλOSΪ29.4¸öÔ¡£Î´·¢ÏÖÐµİ²È«ÐÔÐźÅ¡£

    ´´ÐÂÑо¿ 5




    ±êÌ⣺EGFR-mutant Advanced NSCLC Patients Continuously Benefit From Aumolertinib as Post Secone-Line Treatment

    °¢ÃÀÌæÄá¶þÏßÖÎÁÆEGFR Í»±äNSCLC»¼Õß½øÕ¹ºóÈÔ»ñÒæ

    ×÷ÕߣºÁõÖÇ»ª ½­Î÷Ê¡Ö×ÁöÒ½Ôº

    ÏòÉÏ»¬¶¯ÔÄÀÀ

    ±¾Ñо¿»Ø¹ËÐÔ·ÖÎöÁË2020Äê4ÔÂÖÁ2024Äê4ÔÂÆÚ¼ä½­Î÷Ê¡10¶à¼ÒÒ½ÁÆÖÐÐĵĹ²32ÃûEGFRÍ»±äÍíÆÚNSCLC»¼Õß¡£ËùÓл¼Õß¾ù¿Ú·þ°¢ÃÀÌæÄᣨ110mg£¬Ã¿ÈÕÒ»´Î£©×÷Ϊ¶þÏßÖÎÁÆ¡£¼²²¡½øÕ¹ºó£¬»¼Õß½ÓÊܰ¢ÃÀÌæÄá¼ÓÁ¿£¨165mg/220mg£©»òÁªºÏÖÎÁÆ£¨°¢ÃÀÌæÄáÁªºÏ»¯ÁÆ¡¢VEGFR ÒÖÖÆ¼Á»ò·ÅÁÆ£©¡£PFS1 ¶¨ÒåΪ°¢ÃÀÌæÄáÊ״θøµÏÍþ¹ú¼ÊÖÁ³õʼ½øÕ¹µÄʱ¼ä£¬PFS2 ¶¨ÒåΪÇл»ÖÎÁÆ·½°¸ºóÖÁµÚ¶þ´Î½øÕ¹µÄʱ¼ä¡£Ö÷ÒªÑо¿ÖÕµãΪmPFS2£¬´ÎÒªÖÕµã°üÀ¨ mPFS1¡¢ORR¡¢DCR ºÍ°²È«ÐÔ¡£½ØÖÁÊý¾Ý½ØÖ¹ÈÕÆÚ£¨2024Äê12Ô£©£¬32Àý»¼ÕßÖÐλÄêÁäΪ61Ë꣨·¶Î§48-81Ë꣩£¬Å®ÐÔÕ¼±È59.4%¡£28Àý»¼ÕßµÄECOGÆÀ·Ö´óÓÚ1·Ö¡£mPFS1Ϊ15¸öÔ£¨95%CI£º12.1-17.7£©¡£30Àý»¼Õß¼ÌÐø½ÓÊܰ¢ÃÀÌæÄá¼ÓÁ¿»òÁªºÏÖÎÁÆ¡£mPFS2Ϊ14¸öÔ£¨95%CI£º5.4-22.8£©¡£°²È«ÐÔÓëÏÈǰÁÙ´²ÊÔÑéÒ»Ö£¬Î´¹Û²ìµ½¡Ý3¼¶²»Á¼Ê¼þ¡£

    ´´ÐÂÑо¿ 6




    ±êÌ⣺High-Dose Aumolertinib as First-Line Treatment in Advanced NSCLC Patients Harboring EGFR 21L858R Mutation (AHEAD)

    ¸ß¼ÁÁ¿°¢ÃÀÌæÄáÒ»ÏßÖÎÁÆEGFR 21L85Í»±äµÄÍíÆÚ·ÇСϸ°û·Î°©»¼Õߣ¨AHEAD£©

    ×÷ÕߣºÁÖÁ¢Æ½ ·¬Ø®ÖÐÐÄÒ½Ôº

    ÏòÉÏ»¬¶¯ÔÄÀÀ

    ±¾Ñо¿ÊÇÒ»Ïîµ¥±Û¡¢Ç°Õ°ÐԵĢòÆÚÁÙ´²ÊÔÑ飬ÄâÕÐļ 122 Àý¼ÈÍùδ½ÓÊܹý¿¹Ö×ÁöÖÎÁÆµÄ EGFR L858RÍ»±ä·ÇСϸ°û·Î°©»¼Õß¡£ËùÓл¼Õß½«¿Ú·þ¸ß¼ÁÁ¿°¢ÃÀÌæÄᣨ165mg ÿÈÕÒ»´Î£©Ö±ÖÁ¼²²¡½øÕ¹»òÎÞ·¨ÄÍÊÜ¡£Ö÷ÒªÑо¿ÖÕµãÊÇPFS£¬´ÎÒªÖÕµã°üÀ¨ ORR¡¢DCR¡¢DoR¡¢OS ºÍ°²È«ÐԵȡ£±¾Ñо¿Ö¼ÔÚ̽Ë÷Ò»ÖÖÑÓ³¤ EGFR L858RÍ»±äÐÍÍíÆÚ·ÇСϸ°û·Î°©»¼ÕßÉú´æÆÚ£¬Í¬Ê±±£Ö¤»¼Õß°²È«ÐÔºÍÒÀ´ÓÐÔµÄÖÎÁÆ·½°¸¡£ÁÙ´²ÊÔÑéÕÐChiCTR2500095661£©ÕýÔÚ½øÐÐÖС£



    ¹ØÓÚELCC


    ELCC£¨European Lung Cancer Conference£¬Å·Ö޷ΰ©´ó»á£©ÊÇÓÉÅ·ÖÞÖ×ÁöÄÚ¿ÆÑ§»á£¨ESMO£©Óë¹ú¼Ê·Î°©Ñо¿Ð­»á£¨IASLC£©ÁªºÏÖ÷°ìµÄȨÍþѧÊõ»áÒ飬ÖÂÁ¦ÓÚÍÆ¶¯·Î°©ÁìÓòµÄ»ù´¡Ñо¿¡¢ÁÙ´²ÕïÁÆÓë¶àѧ¿ÆÐ­×÷·¢Õ¹¡£×Ô´´°ìÒÔÀ´£¬ELCCÒѳÉΪȫÇò·Î°©×¨¼Ò¡¢¿ÆÑÐÈËÔ±¼°Ò½ÁÆ´ÓÒµÕß½»Á÷Ç°ÑØ³É¹û¡¢·ÖÏíʵ¼ù¾­ÑéµÄÖØÒª¹ú¼Êƽ̨¡£



    ¹ØÓÚ°¢ÃÀÀÖ?


    ×÷ΪÖйúÊ׸öÔ­ÑÐÈý´úEGFR-TKI£¬°¢ÃÀÀÖ?£¨¼×»ÇËá°¢ÃÀÌæÄáÆ¬£©´´ÐÂÐÔµØÒýÈë»·±û»ù½á¹¹£¬¾ßÓÐÁ¼ºÃµÄÖ¬ÈÜÐÔºÍÎȶ¨ÐÔ£¬ÄܸüºÃµØÍ¸¹ýѪÄÔÆÁÕÏ£¬ÇÒ²»Á¼·´Ó¦·¢ÉúÂʵ͡£Ä¿Ç°£¬°¢ÃÀÀÖ?ÒÑÓÐÈýÏîÊÊÓ¦Ö¢»ñÅúÉÏÊУ¬·Ö±ðÊÇ£º¶þÏßÖÎÁƼÈÍù¾­EGFR-TKIÖÎÁƽøÕ¹£¬ÇÒT790MÍ»±äÑôÐԵľֲ¿ÍíÆÚ»ò×ªÒÆÐÔNSCLC»¼Õߣ¬Ò»ÏßÖÎÁƾßÓÐEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äÑôÐԵľֲ¿ÍíÆÚ»ò×ªÒÆÐÔNSCLC³ÉÈË»¼Õߣ¬ÒÔ¼°º¬²¬¸ùÖÎÐÔ·Å»¯Áƺóδ³öÏÖ¼²²¡½øÕ¹µÄ²»¿ÉÇгýµÄ¾Ö²¿ÍíÆÚEGFRÍâÏÔ×Ó19ȱʧ»òÍâÏÔ×Ó21£¨L858R£©Öû»Í»±äµÄNSCLC»¼ÕßÖÎÁÆ¡£



    ¹ØÓÚµÏÍþÖÆµÏÍþ¹ú¼Ê


    µÏÍþÖÆµÏÍþ¹ú¼ÊÊÇÖйúÁìÏȵĴ´ÐÂÇý¶¯ÐÍÖÆµÏÍþ¹ú¼ÊÆóÒµ£¬ÒÔ¡¸³ÖÐø´´Ð£¬Ìá¸ßÈËÀàÉúÃüÖÊÁ¿¡¹ÎªÊ¹Ãü£¬ÖØµã¹Ø×¢¿¹Ö×Áö¡¢¿¹¸ÐȾ¡¢ÖÐÊàÉñ¾­ÏµÍ³¡¢´úл¼°×ÔÉíÃâÒßµÈÖØ´ó¼²²¡ÖÎÁÆÁìÓò¡£½ØÖÁĿǰ£¬¹«Ë¾ÒÑÉÏÊÐ7¿î´´ÐµÏÍþ¹ú¼Ê£¬ÐγÉÁ˷ḻµÄ²úÆ·¹ÜÏß¡£µÏÍþÖÆµÏÍþ¹ú¼ÊÁ¬Ðø¶àÄêλ¾ÓÈ«ÇòÖÆµÏÍþ¹ú¼ÊÆóÒµ°ÙÇ¿¡¢ÖйúÒ½µÏÍþ¹ú¼ÊÑз¢²úÆ·Ïß×î¼Ñ¹¤ÒµÆóҵǰ3Ç¿£¬Êǹú¼ÒÖØµã¸ßм¼ÊõÆóÒµ¡¢¹ú¼Ò¼¼Êõ´´ÐÂʾ·¶ÆóÒµ¡£µÏÍþÖÆµÏÍþ¹ú¼ÊÓÚ2019Äê6ÔÂÔÚÏã¸ÛÁª½»Ëù¹ÒÅÆÉÏÊУ¨¹ÉƱ´úÂ룺03692.HK£©¡£

    ¸ü¶àÐÅÏ¢Çë·ÃÎÊ£º/¡£


    ÉùÃ÷£º

    1¡¢±¾¹«¸æ½ö¹©Ò½ÁÆÎÀÉúרҵÈËÊ¿²ÎÔÄ£¬·Ç¹ã¸æÓÃ;¡£

    2¡¢µÏÍþÖÆµÏÍþ¹ú¼Ê²»ÍƼöÈκÎδ»ñÅúµÏÍþ¹ú¼ÊƷʹÓúÍ/»òδ»ñÅúÊÊÓ¦Ö¢ÓõÏÍþ¹ú¼Ê£¬Ò಻¶ÔÈκεÏÍþ¹ú¼ÊÆ·ºÍ/»òÊÊÓ¦Ö¢×÷ÍÆ¼ö¡£

    3¡¢±¾¹«¸æÖÐÉæ¼°µÄÐÅÏ¢½ö¹©²Î¿¼£¬Çë×ñ´ÓÒ½Éú»òÆäËûÒ½ÁÆÎÀÉúרҵÈËÊ¿µÄÒâ¼û»òÖ¸µ¼¡£Ò½ÁÆÎÀÉúרҵÈËÊ¿×÷³öµÄÈκÎÓëÖÎÁÆÓйصľö¶¨Ó¦¸ù¾Ý»¼ÕߵľßÌåÇé¿ö²¢×ñÕÕµÏÍþ¹ú¼ÊƷ˵Ã÷Êé¡£

    4¡¢ÈçÐèÁ˽⹫˾ÈκβúÆ·¡¢Ò½ÁÆ»ò¼²²¡µÄÏà¹ØÐÅÏ¢£¬ÇëÎñ±Ø×ÉѯҽÁÆÎÀÉúרҵÈËÊ¿¡£



    ǰհÐÔ˵Ã÷


    ±¾ÐÂΟåÖ¼ÔÚÌṩ¹ØÓÚµÏÍþÖÆµÏÍþ¹ú¼Ê¼¯ÍÅÓÐÏÞ¹«Ë¾¼°Æä¸½Êô¹«Ë¾£¨°üÀ¨Æä×Ó¹«Ë¾£¬Í³³ÆÎª¡°µÏÍþÖÆµÏÍþ¹ú¼Ê¡±£©µÄÐÅÏ¢¡£Ëü²»¹¹³É¶ÔµÏÍþÖÆµÏÍþ¹ú¼Ê»òÈκÎͶ×ʽ¨ÒéµÄÐÅÏ¢Åû¶¡£

    ±¾ÐÂΟå°üº¬µÄÐÅÏ¢¿ÉÄܰüÀ¨ÓëµÏÍþÖÆµÏÍþ¹ú¼ÊÒµÎñºÍ²úƷǰ¾°¡¢¼Æ»®¡¢ÐÅÄî¡¢Ô¤ÆÚºÍ²ßÂÔÏà¹ØµÄǰհÐÔÉùÃ÷¡£ÕâЩÉùÃ÷ÊÇ»ùÓÚÍÆ²âÐÔ¼ÙÉèµÄÔ¤²â£¬²¢²»±£Ö¤Î´À´µÄ±íÏÖ¡£ËüÃÇÊܵ½ÖîÈç¿ÆÑ§¡¢ÉÌÒµ¡¢ÕþÖΡ¢¾­¼Ã¡¢²ÆÎñ¡¢·¨ÂÉÒòËØÒÔ¼°¾ºÕù»·¾³ºÍÉç»áÌõ¼þµÈ·çÏպͲ»È·¶¨ÐÔµÄÓ°Ï죬ÕâЩÒòËØºÜ¶à¶¼ÊǵÏÍþÖÆµÏÍþ¹ú¼ÊÎÞ·¨¿ØÖÆÇÒÄÑÒÔÔ¤²âµÄ£¬Òò´Ëʵ¼Ê½á¹û¿ÉÄÜÓë´Ë´¦ËùÊöÓÐÏÔÖø²îÒ죬ÇÒ¹ýÈ¥µÄ֤ȯ¼Û¸ñÇ÷ÊÆ²»Ó¦×÷ΪδÀ´ÐÐÇéµÄÖ¸µ¼¡£Òò´Ë£¬Í¶×ÊÕßÔÚʹÓÃÕâЩÐÅÏ¢½øÐÐͶ×ʾö²ßʱӦ½÷É÷ÐÐÊ¡£¡°ÖÂÁ¦ÓÚ¡±¡°Ô¤ÆÚ¡±¡°ÏàÐÅ¡±¡°Ô¤²â¡±¡°Òâͼ¡±¡°Ô¤¼Æ¡±¡°¿ÉÄÜ¡±¡°½«¡±¡°Ó¦¸Ã¡±¡°¼Æ»®¡±¡°¼ÌÐø¡±¡°Ä¿±ê¡±¡°¿¼ÂÇ¡±¡°¹À¼Æ¡±¡°Ö¸µ¼¡±¡°Ç±ÔÚ¡±¡°×·Çó¡±ÒÔ¼°ÓÚÈκÎδÀ´¼Æ»®¡¢Ðж¯»òʼþµÄÌÖÂÛÖÐʹÓõÄÀàËÆ´ÊÓïºÍÊõÓ¾ù±íʾǰհÐÔÉùÃ÷¡£

    µÏÍþÖÆµÏÍþ¹ú¼Ê²»³Ðŵ»ò±£Ö¤Ç°Õ°ÐÔÐÅÏ¢µÄ׼ȷÐÔ¡¢¼°Ê±ÐÔ»òÍêÕûÐÔ£¬²¢ÇÒ²»³Ðµ£¸üлòÐÞ¶©ÕâЩǰհÐÔÉùÃ÷µÄÒåÎñ¡£ÎÞÂÛÊǵÏÍþÖÆµÏÍþ¹ú¼Ê»¹ÊÇÆäÈκζ­Ê¡¢Ô±¹¤»ò´úÀíÈË£¬¾ù²»¶ÔÈκÎÖ¤Ã÷²»×¼È·»òÎÞ·¨ÊµÏÖµÄǰհÐÔÉùÃ÷¸ºÔð£¬Ò²²»¶ÔÒòÒÀÀµ±¾ÐÂΟåÖÐÌṩµÄÐÅÏ¢¶ø²úÉúµÄÈκÎËðʧ»òË𺦸ºÔ𣬰üÀ¨µ«²»ÏÞÓÚÖ±½Ó¡¢Å¼È»¡¢¼ä½Ó»ò³Í·£ÐÔµÄË𺦡£




    ¡¾ÍøÕ¾µØÍ¼¡¿¡¾sitemap¡¿